- $513.89m
- $417.99m
- $85.23m
Delcath Systems Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Inc reports results for the quarter ended December 31 - Earnings Summary
Delcath Systems Inc expected to post a loss of 2 cents a share - Earnings Preview
Brief: Delcath Systems Announces Update To National Comprehensive Cancer Network Clinical Practice Guidelines
Brief: Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
Brief: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer
Delcath Systems Inc reports results for the quarter ended September 30 - Earnings Summary
Delcath Systems Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
Delcath Systems rises as co expects wider-than-estimated Q3 revenue
Brief: Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
Brief: Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Inc reports results for the quarter ended in June - Earnings Summary
Delcath Systems Inc expected to post a loss of 36 cents a share - Earnings Preview
Delcath Systems Inc reports results for the quarter ended in March - Earnings Summary
Delcath Systems Inc expected to post a loss of 47 cents a share - Earnings Preview
Delcath Systems Inc expected to post a loss of 47 cents a share - Earnings Preview